Cooper Companies (NASDAQ:COO) Shares Down 3.2% – Here’s What Happened

The Cooper Companies, Inc. (NASDAQ:COO)’s share price traded down 3.2% during trading on Thursday . The company traded as low as $53.15 and last traded at $52.8750. 419,036 shares were traded during mid-day trading, a decline of 83% from the average daily volume of 2,505,022 shares. The stock had previously closed at $54.61.

Trending Headlines about Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Activist investor Jana Partners urged Cooper to conduct an external CEO search, appoint a new board chair and evaluate asset sales. Although the campaign highlights execution problems, investors may view potential leadership and portfolio changes as catalysts for unlocking shareholder value. Reuters activist investor report
• Positive Sentiment: Several directors have recently bought shares, including Lawrence Kurzius’s purchase of 10,000 shares for approximately $549,300. The cluster of insider buying may signal that directors view the selloff as excessive. Director insider purchase report
• Positive Sentiment: Cooper retained CooperSurgical after its strategic review and expanded its share-repurchase authorization to $3 billion. The buyback, combined with reported record free cash flow and an adjusted EPS beat, supports the long-term shareholder-value case. Cooper Companies strategic review and capital plan article
• Neutral Sentiment: Jana’s campaign could lead to strategic improvements, but it also increases uncertainty around management, the board and Cooper’s business portfolio.
• Negative Sentiment: U.S. channel inventory destocking at CooperVision is expected to continue into the fourth quarter, raising questions about near-term demand and revenue growth. The company’s latest quarter beat EPS expectations but missed revenue estimates.
• Negative Sentiment: Investor-law-firm investigations related to the guidance reduction add legal and headline risk, while cautious analyst ratings and prior target-price cuts reflect Cooper’s underperformance versus medical-device peers. Securities investigation notice

Analyst Ratings Changes

A number of brokerages recently weighed in on COO. KeyCorp reissued a “sector weight” rating on shares of Cooper Companies in a report on Friday, June 5th. Needham & Company LLC dropped their target price on Cooper Companies from $86.00 to $73.00 and set a “buy” rating for the company in a research report on Thursday, September 10th. Stifel Nicolaus set a $70.00 price target on Cooper Companies and gave the company a “buy” rating in a research note on Thursday, September 10th. BNP Paribas Exane cut their price objective on shares of Cooper Companies from $95.00 to $92.00 and set an “outperform” rating on the stock in a report on Monday, June 8th. Finally, Mizuho set a $75.00 price objective on shares of Cooper Companies and gave the company an “outperform” rating in a report on Thursday, September 10th. Five equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $71.47.

Cooper Companies Price Performance

The firm has a market cap of $10.51 billion, a price-to-earnings ratio of 18.87, a P/E/G ratio of 2.19 and a beta of 0.82. The company has a current ratio of 1.22, a quick ratio of 0.73 and a debt-to-equity ratio of 0.23. The company has a 50 day moving average of $69.92 and a 200 day moving average of $68.68.

Cooper Companies (NASDAQ:COO) last posted its earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.12 by $0.03. The firm had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.10 billion. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%.The company’s revenue was up .5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.49 earnings per share. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. Equities research analysts predict that The Cooper Companies, Inc. will post 4.53 EPS for the current fiscal year.

Cooper Companies announced that its board has initiated a stock buyback plan on Wednesday, September 9th that permits the company to repurchase $3.00 billion in outstanding shares. This repurchase authorization permits the medical device company to reacquire up to 22.7% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board of directors believes its stock is undervalued.

Insider Transactions at Cooper Companies

In other Cooper Companies news, Director Lawrence Kurzius acquired 10,000 shares of the stock in a transaction dated Monday, September 14th. The shares were bought at an average cost of $53.91 per share, for a total transaction of $539,100.00. Following the completion of the acquisition, the director directly owned 21,099 shares of the company’s stock, valued at approximately $1,137,447.09. This trade represents a 90.10% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Paul Keel acquired 4,701 shares of the business’s stock in a transaction dated Friday, September 11th. The stock was acquired at an average cost of $53.18 per share, for a total transaction of $249,999.18. Following the transaction, the director owned 4,701 shares of the company’s stock, valued at $249,999.18. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders acquired 34,701 shares of company stock valued at $1,880,039 in the last ninety days. 2.08% of the stock is currently owned by corporate insiders.

Institutional Trading of Cooper Companies

Institutional investors and hedge funds have recently bought and sold shares of the business. Avalon Trust Co bought a new position in shares of Cooper Companies in the second quarter valued at about $25,000. Root Financial Partners LLC grew its stake in shares of Cooper Companies by 104.5% in the fourth quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock valued at $26,000 after acquiring an additional 162 shares in the last quarter. SJS Investment Consulting Inc. boosted its stake in shares of Cooper Companies by 107.5% in the first quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company’s stock valued at $26,000 after buying an additional 187 shares during the period. Elevation Wealth Partners LLC boosted its stake in shares of Cooper Companies by 1,136.4% in the second quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company’s stock valued at $29,000 after buying an additional 375 shares during the period. Finally, Continuum Advisory LLC acquired a new position in Cooper Companies in the second quarter valued at about $30,000. Institutional investors own 24.39% of the company’s stock.

Cooper Companies Company Profile

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.